Selegiline monotherapy in the treatment of Parkinson's disease

Publisher Website
Google Scholar
Abstract
MAO has since been discovered to exist in two forms, initially defined by their sensitivity to the inhibiting drug clorgyline, with type A being more sensitive than type B. [5] MAO found in the brain is predominantly type B, while MAO in the gut is mainly type A. [6] Brain dopamine may be predominantly metabolized by MAO-B, but the possible importance of intraneuronal MAO-A in the brain should be considered. A new class of MAO inhibitors has been developed [7,8] that are selective, irreversible inhibitors of MAO-B, thus able to preserve endogenous and exogenous dopamine without the MAO-A mediated "cheese" effect. One of these drugs, isopropylmethylpropargylamine hydrochloride, known as deprenyl or selegiline, has undergone further clinical development.